Table 1.
Demographic information for all samples used in this study
| AML |
|||
|---|---|---|---|
| CHARM cohort | Additional validation samples | Normal | |
| (n = 15) | (n = 13) | (n = 15) | |
| Gender [Number of males (%)] | 11 (73%) | 4 (31%) | 7 (47%) |
| Age (median, range)1 | 38 (18–62) | 59 (20–71) | 42 (23–64) |
| Cytogenetic risk | |||
| Low2 | 30 (24–60, n = 5) | 68 (20–71, n = 3) | - |
| Mid | 38 (18–62, n = 5) | 59 (48–70, n = 5) | - |
| High3 | 45 (18–58, n = 5) | 49 (21–64, n = 5) | - |
| Blast percentage (median, range) | 77% (39%-96%) | 88% (17%-99%) | |
1.
Samples were age matched within the CHARM cohort (P = 0.94 by Kruskal-Wallis test) and additional validation cohort (P = 0.53).
2.
Low-risk AML was defined as patients with t(8;21) or inv(16);
3.
High-risk AML patients in this study all had complex karyotype.